Protective Effects of Oral L-Arginine CI-AKI

Protective Effects of Oral L-Arginine Supplement in Patients With CKD After Intravenous Contrast Media Injection

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02455960

Enrollment

112

Registered

2015-05-28

Start date

2014-09-30

Completion date

2016-05-31

Last updated

2015-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast Induced AKI

Brief summary

This trial was performed to examine the efficacy of oral L-arginine for preventing CI-AKI in chronic kidney disease (CKD) patients.

Detailed description

Contrast-induced acute kidney injury (CI-AKI) is a common complication in hospitalized patients. Nitric oxide-signal transduction plays an important role in prevention of CI-AKI. L-Arginine is an amino acid involved in ammonia detoxification, and is well known as a precursor to nitric oxide, a key component of endothelial-derived relaxing factor. This is a prospective randomized, double blind, placebo controlled trial among CKD stage 3-4 patients undergoing computer tomography. Eligible patients were randomly assigned to two groups: (1) arginine 3 g/day or 6 capsules per day, and (2) placebo 6 capsules per day for 3 days before contrast media injection. Serum cystatin C, serum creatinine and estimated GFR was measured at baseline and 48 hours after procedure.

Interventions

DIETARY_SUPPLEMENTPlacebo

DIETARY_SUPPLEMENTL-arginine

Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age ≥ 18 years * Stable CKD stage 3-4 patients * Patients undergoing elective contrast media injection

Exclusion criteria

* History of arginine allergy * Acute kidney injury diagnosed within 4 weeks * Active infection/sepsis * Severe liver disease

Design outcomes

Primary

Measure	Time frame
Incidence of Contrast-induced acute kidney injury (CI-AKI)	48 hours

Secondary

Measure	Time frame
Number of Adverse effects	48 hours

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026